126 related articles for article (PubMed ID: 2202731)
1. Comparative effect of cisplatin, spiroplatin, carboplatin and iproplatin in a human tumor clonogenic assay.
Schroyens W; Dodion P; Rozencweig M
J Cancer Res Clin Oncol; 1990; 116(4):392-6. PubMed ID: 2202731
[TBL] [Abstract][Full Text] [Related]
2. Comparative effect of cisplatin, spiroplatin, carboplatin, iproplatin and JM40 in a human myeloid clonogenic assay.
Schroyens WA; Meeker JB; Dodion P; Stryckmans PA; Rozencweig M
Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1309-12. PubMed ID: 3053206
[TBL] [Abstract][Full Text] [Related]
3. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.
Boven E; van der Vijgh WJ; Nauta MM; Schlüper HM; Pinedo HM
Cancer Res; 1985 Jan; 45(1):86-90. PubMed ID: 4038381
[TBL] [Abstract][Full Text] [Related]
4. [Antitumor effect of carboplatin and iproplatin on human urinary bladder and prostatic cancers grown in nude mice].
Hasegawa J; Kawamura N; Yamada S; Tsuboi N; Akimoto M
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3279-83. PubMed ID: 3318705
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of platinol analogs using the M5076 murine sarcoma.
Rose WC
Anticancer Res; 1986; 6(4):557-62. PubMed ID: 3530116
[TBL] [Abstract][Full Text] [Related]
6. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
7. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study.
Weiss G; Green S; Alberts DS; Thigpen JT; Hines HE; Hanson K; Pierce HI; Baker LH; Goodwin JW
Eur J Cancer; 1991; 27(2):135-8. PubMed ID: 1827275
[TBL] [Abstract][Full Text] [Related]
8. Comparison of platinum concentrations in human head and neck tumours following administration of carboplatin, iproplatin or cisplatin.
Hecquet B; Caty A; Fournier C; Lefebvre JL; Adenis L
Bull Cancer; 1987; 74(4):433-6. PubMed ID: 3311237
[TBL] [Abstract][Full Text] [Related]
9. In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin.
Dodion P; Sanders C; Georges P; Kenis Y
Cancer Chemother Pharmacol; 1988; 22(1):80-2. PubMed ID: 3293841
[TBL] [Abstract][Full Text] [Related]
10. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study.
McGuire WP; Arseneau J; Blessing JA; DiSaia PJ; Hatch KD; Given FT; Teng NN; Creasman WT
J Clin Oncol; 1989 Oct; 7(10):1462-8. PubMed ID: 2674333
[TBL] [Abstract][Full Text] [Related]
11. The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: a cautionary note.
Goddard PM; Valenti MR; Harrap KR
Ann Oncol; 1991 Sep; 2(8):535-40. PubMed ID: 1793720
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro.
Harstrick A; Casper J; Guba R; Wilke H; Poliwoda H; Schmoll HJ
Cancer; 1989 Mar; 63(6):1079-83. PubMed ID: 2645036
[TBL] [Abstract][Full Text] [Related]
13. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.
Hills CA; Kelland LR; Abel G; Siracky J; Wilson AP; Harrap KR
Br J Cancer; 1989 Apr; 59(4):527-34. PubMed ID: 2653399
[TBL] [Abstract][Full Text] [Related]
14. Lung tumour growth delay and normal tissue toxicity induced by three cytotoxic platinum drugs.
van Rongen E; Kal HB; Kuijpers WC; van Berkel AH
Strahlenther Onkol; 1992 May; 168(5):300-7. PubMed ID: 1598667
[TBL] [Abstract][Full Text] [Related]
15. In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas.
Rose WC; Basler GA
In Vivo; 1990; 4(6):391-6. PubMed ID: 2103379
[TBL] [Abstract][Full Text] [Related]
16. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
Mellish KJ; Kelland LR; Harrap KR
Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
[TBL] [Abstract][Full Text] [Related]
17. [Organoplatinum compounds. 1987 update].
Extra JM; Espie M; Calvo F; Marty M
Nouv Rev Fr Hematol (1978); 1988; 30(1-2):123-30. PubMed ID: 3290835
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer. The EORTC Early Clinical Trials Group and the EORTC Data Center.
Vermorken JB; Gundersen S; Clavel M; Smyth JF; Dodion P; Renard J; Kaye SB
Ann Oncol; 1993 Apr; 4(4):303-6. PubMed ID: 8518220
[TBL] [Abstract][Full Text] [Related]
19. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
20. Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin.
Steerenberg PA; Vendrik CP; de Jong WH; de Groot G; Fichtinger-Schepman AM; Scheefhals AP; Schornagel JH
Cancer Chemother Pharmacol; 1988; 22(1):51-7. PubMed ID: 3293840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
